Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients

BIG-RENAPE Working Group, PSOGI Working Group

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Peritoneal carcinomatosis or pseudomyxoma peritonei from urachus is a rare form of presentation, often diagnosed at an advanced state of tumor burden. Because of its rarity, little is known about its natural history, prognosis, or optimal treatment. We searched a large international multicenter database of peritoneal surface disease to identify cases of peritoneal carcinomatosis of urachus that were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at expert centers. The aim is to improve knowledge and understanding of the disease and standardize its treatment. Methods: A prospective multicenter international database was retrospectively searched to identify all patients with urachus tumor and peritoneal metastases who underwent CRS and HIPEC through the Peritoneal Surface Oncology Group International (PSOGI). Postoperative complications, long-term results, and principal prognostic factors were analyzed. Results: The analysis included 36 patients. After median follow-up of 48 months, median overall survival (OS) was 58.5 months. Three- and 5-year OS was 55.4 and 46.2%, respectively. Patients who underwent complete macroscopic CRS had significantly better survival than those treated with incomplete CRS, with median OS not achieved and of 20.1 months, respectively [95% confidence interval (CI) 4.4–30.5, p OpenSPiltSPi 0.001]. There were no postoperative deaths, and 37.9% of patients had major complications. Conclusion: CRS and HIPEC may increase long-term survival in selected patients with peritoneal metastases of urachus origin, especially when complete CRS is achieved.

Original languageEnglish
Pages (from-to)1094-1100
Number of pages7
JournalAnnals of Surgical Oncology
Volume25
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Urachus
Registries
Carcinoma
Drug Therapy
Survival
Peritoneal Diseases
Pseudomyxoma Peritonei
Databases
Neoplasm Metastasis
Tumor Burden
Natural History
Confidence Intervals
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) : An International Registry of 36 Patients. / BIG-RENAPE Working Group; PSOGI Working Group.

In: Annals of Surgical Oncology, Vol. 25, No. 4, 01.04.2018, p. 1094-1100.

Research output: Contribution to journalArticle

@article{6ea283272be14a6bbb70772ef4c1a0c7,
title = "Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients",
abstract = "Purpose: Peritoneal carcinomatosis or pseudomyxoma peritonei from urachus is a rare form of presentation, often diagnosed at an advanced state of tumor burden. Because of its rarity, little is known about its natural history, prognosis, or optimal treatment. We searched a large international multicenter database of peritoneal surface disease to identify cases of peritoneal carcinomatosis of urachus that were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at expert centers. The aim is to improve knowledge and understanding of the disease and standardize its treatment. Methods: A prospective multicenter international database was retrospectively searched to identify all patients with urachus tumor and peritoneal metastases who underwent CRS and HIPEC through the Peritoneal Surface Oncology Group International (PSOGI). Postoperative complications, long-term results, and principal prognostic factors were analyzed. Results: The analysis included 36 patients. After median follow-up of 48 months, median overall survival (OS) was 58.5 months. Three- and 5-year OS was 55.4 and 46.2{\%}, respectively. Patients who underwent complete macroscopic CRS had significantly better survival than those treated with incomplete CRS, with median OS not achieved and of 20.1 months, respectively [95{\%} confidence interval (CI) 4.4–30.5, p OpenSPiltSPi 0.001]. There were no postoperative deaths, and 37.9{\%} of patients had major complications. Conclusion: CRS and HIPEC may increase long-term survival in selected patients with peritoneal metastases of urachus origin, especially when complete CRS is achieved.",
author = "{BIG-RENAPE Working Group} and {PSOGI Working Group} and Frederic Mercier and Guillaume Passot and Laurent Villeneuve and Levine, {Edward A.} and Yutaka Yonemura and Diane Go{\'e}r{\'e} and Sugarbaker, {Paul H.} and Christelle Marolho and Bartlett, {David L.} and Olivier Glehen and J. Abba and K. Abboud and M. Alyami and C. Arvieux and N. Bakrin and Bereder, {J. M.} and D. Bouzard and C. Brigand and S. Carr{\`e}re and D. Delroeux and F. Dumont and C. Eveno and O. Facy and F. Guyon and G. Ferron and R. Kianmanesh and {Lo Dico}, R. and G. Lorimier and F. Marchal and P. Mariani and P. Meeus and S. Msika and P. Ortega-Deballon and B. Paquette and P. Peyrat and N. Pirro and M. Pocard and J. Porcheron and F. Quenet and P. Rat and O. Sgarbura and E. Thibaudeau and Tuech, {J. J.} and F. Zinzindohoue and Ahrendt, {S. A.} and E. Akaishi and Baik, {S. H.} and D. Baratti and A. Bhatt and Mao-Chih Hsieh",
year = "2018",
month = "4",
day = "1",
doi = "10.1245/s10434-017-6299-z",
language = "English",
volume = "25",
pages = "1094--1100",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

T2 - An International Registry of 36 Patients

AU - BIG-RENAPE Working Group

AU - PSOGI Working Group

AU - Mercier, Frederic

AU - Passot, Guillaume

AU - Villeneuve, Laurent

AU - Levine, Edward A.

AU - Yonemura, Yutaka

AU - Goéré, Diane

AU - Sugarbaker, Paul H.

AU - Marolho, Christelle

AU - Bartlett, David L.

AU - Glehen, Olivier

AU - Abba, J.

AU - Abboud, K.

AU - Alyami, M.

AU - Arvieux, C.

AU - Bakrin, N.

AU - Bereder, J. M.

AU - Bouzard, D.

AU - Brigand, C.

AU - Carrère, S.

AU - Delroeux, D.

AU - Dumont, F.

AU - Eveno, C.

AU - Facy, O.

AU - Guyon, F.

AU - Ferron, G.

AU - Kianmanesh, R.

AU - Lo Dico, R.

AU - Lorimier, G.

AU - Marchal, F.

AU - Mariani, P.

AU - Meeus, P.

AU - Msika, S.

AU - Ortega-Deballon, P.

AU - Paquette, B.

AU - Peyrat, P.

AU - Pirro, N.

AU - Pocard, M.

AU - Porcheron, J.

AU - Quenet, F.

AU - Rat, P.

AU - Sgarbura, O.

AU - Thibaudeau, E.

AU - Tuech, J. J.

AU - Zinzindohoue, F.

AU - Ahrendt, S. A.

AU - Akaishi, E.

AU - Baik, S. H.

AU - Baratti, D.

AU - Bhatt, A.

AU - Hsieh, Mao-Chih

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Purpose: Peritoneal carcinomatosis or pseudomyxoma peritonei from urachus is a rare form of presentation, often diagnosed at an advanced state of tumor burden. Because of its rarity, little is known about its natural history, prognosis, or optimal treatment. We searched a large international multicenter database of peritoneal surface disease to identify cases of peritoneal carcinomatosis of urachus that were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at expert centers. The aim is to improve knowledge and understanding of the disease and standardize its treatment. Methods: A prospective multicenter international database was retrospectively searched to identify all patients with urachus tumor and peritoneal metastases who underwent CRS and HIPEC through the Peritoneal Surface Oncology Group International (PSOGI). Postoperative complications, long-term results, and principal prognostic factors were analyzed. Results: The analysis included 36 patients. After median follow-up of 48 months, median overall survival (OS) was 58.5 months. Three- and 5-year OS was 55.4 and 46.2%, respectively. Patients who underwent complete macroscopic CRS had significantly better survival than those treated with incomplete CRS, with median OS not achieved and of 20.1 months, respectively [95% confidence interval (CI) 4.4–30.5, p OpenSPiltSPi 0.001]. There were no postoperative deaths, and 37.9% of patients had major complications. Conclusion: CRS and HIPEC may increase long-term survival in selected patients with peritoneal metastases of urachus origin, especially when complete CRS is achieved.

AB - Purpose: Peritoneal carcinomatosis or pseudomyxoma peritonei from urachus is a rare form of presentation, often diagnosed at an advanced state of tumor burden. Because of its rarity, little is known about its natural history, prognosis, or optimal treatment. We searched a large international multicenter database of peritoneal surface disease to identify cases of peritoneal carcinomatosis of urachus that were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at expert centers. The aim is to improve knowledge and understanding of the disease and standardize its treatment. Methods: A prospective multicenter international database was retrospectively searched to identify all patients with urachus tumor and peritoneal metastases who underwent CRS and HIPEC through the Peritoneal Surface Oncology Group International (PSOGI). Postoperative complications, long-term results, and principal prognostic factors were analyzed. Results: The analysis included 36 patients. After median follow-up of 48 months, median overall survival (OS) was 58.5 months. Three- and 5-year OS was 55.4 and 46.2%, respectively. Patients who underwent complete macroscopic CRS had significantly better survival than those treated with incomplete CRS, with median OS not achieved and of 20.1 months, respectively [95% confidence interval (CI) 4.4–30.5, p OpenSPiltSPi 0.001]. There were no postoperative deaths, and 37.9% of patients had major complications. Conclusion: CRS and HIPEC may increase long-term survival in selected patients with peritoneal metastases of urachus origin, especially when complete CRS is achieved.

UR - http://www.scopus.com/inward/record.url?scp=85038023367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038023367&partnerID=8YFLogxK

U2 - 10.1245/s10434-017-6299-z

DO - 10.1245/s10434-017-6299-z

M3 - Article

C2 - 29238881

AN - SCOPUS:85038023367

VL - 25

SP - 1094

EP - 1100

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -